Related Experiment Video
Updated: Jul 6, 2025
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Self-Assembly of Erlotinib-Platinum(II) Complexes for Epidermal Growth Factor Receptor-Targeted Photodynamic Therapy
Haobing Wang1, Yidan Lai1,2, Dan Li1
1College of Chemistry and Environmental Engineering, Shenzhen University, Shenzhen 518060, China.
Abstract:
Due to cell mutation and self-adaptation, the application of clinical drugs with early epidermal growth factor receptor (EGFR)-targeted inhibitors is severely limited. To overcome this limitation, herein, the synthesis and in-depth biological evaluation of an erlotinib-platinum(II) complex as an EGFR-targeted anticancer agent is reported. The metal complex is able to self-assemble inside an aqueous solution and readily form nanostructures with strong photophysical properties. While being poorly toxic toward healthy cells and upon treatment in the dark, the compound was able to induce a cytotoxic effect in the very low micromolar range upon irradiation against EGFR overexpressing (drug resistant) human lung cancer cells as well as multicellular tumor spheroids. Mechanistic insights revealed that the compound was able to selectively degrade the EGFR using the lysosomal degradation pathway upon generation of singlet oxygen at the EGFR. We are confident that this work will open new avenues for the treatment of EGFR-overexpressing tumors.
Insights
A novel erlotinib-platinum(II) complex shows promise as an EGFR-targeted anticancer drug. This metal complex self-assembles into nanostructures, effectively targeting drug-resistant lung cancer cells with minimal toxicity to healthy cells.
Area of Science:
- Medicinal Chemistry
- Nanotechnology
- Oncology
Background:
- Clinical application of epidermal growth factor receptor (EGFR)-targeted inhibitors is limited by cell mutation and self-adaptation.
- Development of novel anticancer agents is crucial for overcoming drug resistance in cancers like lung cancer.
Purpose of the Study:
- To synthesize and evaluate an erlotinib-platinum(II) complex as a novel EGFR-targeted anticancer agent.
- To investigate the self-assembly, photophysical properties, and biological activity of the metal complex.
- To elucidate the mechanism of action against EGFR-overexpressing cancer cells.
Main Methods:
- Synthesis of an erlotinib-platinum(II) complex.
- Characterization of self-assembly into nanostructures in aqueous solution.
- In vitro cytotoxicity assays against EGFR-overexpressing human lung cancer cells and multicellular tumor spheroids.
- Photophysical property analysis and mechanistic studies involving singlet oxygen generation and lysosomal degradation pathways.
Main Results:
- The erlotinib-platinum(II) complex self-assembles into nanostructures with significant photophysical properties.
- The compound exhibits low toxicity to healthy cells and minimal dark toxicity.
- Effective induction of cytotoxic effects in the low micromolar range against drug-resistant lung cancer cells and tumor spheroids upon irradiation.
- Demonstrated selective degradation of EGFR via the lysosomal pathway, triggered by singlet oxygen generation at the target.
Conclusions:
- The synthesized erlotinib-platinum(II) complex represents a promising EGFR-targeted photodynamic anticancer therapeutic.
- This approach overcomes limitations associated with conventional EGFR inhibitors by utilizing a metal-based strategy.
- The findings open new therapeutic avenues for treating EGFR-overexpressing tumors, particularly those resistant to existing therapies.
More Related Videos
08:35Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
11:04An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model
Published on: January 13, 2023
